CurrentUnitedHealthcarePolicy N/A

Sutent (sunitinib) prior authorization — Pharmacy Clinical Pharmacy Programs

Prior authorization and notification criteria for coverage of Sutent (sunitinib malate) for specified oncologic indications under UnitedHealthcare Pharmacy Clinical Pharmacy Programs; applies to members subject to the payer's pharmacy benefit (members <19 auto-process).

Policy Summary

PayerUnitedHealthcare

PolicySutent (sunitinib) prior authorization — Pharmacy Clinical Pharmacy Programs

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateMar 1, 2025

Key ActionSubmit prior authorization documenting diagnosis and required clinical history; members under 19 auto-process.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization duration

automatic approval under 19members <19 auto-process

multiplemultiple oncology indications

NCCN 1/2A/2BNCCN evidence categories

Coverage Criteria by Indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Patients <19

Covered for patients under 19 years of age

Patients <19: Patient is less than 19 years of age

Authorization issued for 12 months

GIST Initial Authorization

Gastrointestinal Stromal Tumor (GIST) - Initial Authorization

GIST initial

GIST second criterion: (a) History of disease progression on, contraindication to, or intolerance to Gleevec (imatinib), Stivarga (regorafenib), or standard dose Qinlock (ripretinib)
GIST second criterion: (b) SDH-deficient GIST

GIST Reauthorization

GIST - Reauthorization

GIST reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

RCC Initial Authorization

Renal Cell Carcinoma (RCC) - Initial Authorization

RCC initial: Diagnosis of renal cell carcinoma (RCC)

AND one of: disease has relapsed OR disease is advanced OR (used in adjuvant setting AND patient has high risk of recurrence following nephrectomy); Authorization issued for 12 months.

RCC Reauthorization

RCC - Reauthorization

RCC reauth: Patient does not show evidence of progressive disease while on Sutent therapy

pNET Initial Authorization

Pancreatic Neuroendocrine Tumors (pNET) - Initial Authorization

pNET initial: Diagnosis of progressive pancreatic neuroendocrine tumors (pNET)

pNET Reauthorization

pNET - Reauthorization

pNET reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Soft Tissue Sarcomas Initial Authorization

Selected Soft Tissue Sarcomas - Initial Authorization

Sarcoma types: Diagnosis of one of: Alveolar soft part sarcoma (ASPS); Angiosarcoma; Solitary fibrous tumor/hemangiopericytoma; Extraskeletal myxoid chondrosarcoma

Authorization issued for 12 months

Soft Tissue Sarcomas Reauthorization

Selected Soft Tissue Sarcomas - Reauthorization

Sarcoma reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Thyroid Carcinoma Initial Authorization

Thyroid Carcinoma - Initial Authorization

Thyroid carcinoma pathways: Either: (1) Diagnosis of follicular, oncocytic, or papillary carcinoma AND unresectable locoregional recurrent OR persistent OR metastatic disease AND symptomatic OR progressive disease AND disease refractory to radioactive iodine; OR (2) Diagnosis of medullary thyroid carcinoma AND progressive disease OR symptomatic metastatic disease AND clinical trials or preferred systemic therapy options are not available/appropriate OR progression on preferred systemic therapy (e.g., vandetanib, cabozantinib).

Thyroid Reauthorization

Thyroid Carcinoma - Reauthorization

Thyroid reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Chordoma Initial Authorization

Chordoma - Initial Authorization

Chordoma initial: Diagnosis of recurrent chordoma

Authorization issued for 12 months

Chordoma Reauthorization

Chordoma - Reauthorization

Chordoma reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Meningioma Initial Authorization

Meningioma - Initial Authorization

Meningioma initial: Diagnosis of surgically inaccessible meningiomas AND (disease is recurrent OR disease is progressive) AND further radiation is not possible

Meningioma Reauthorization

Meningioma - Reauthorization

Meningioma reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Thymic Carcinoma Initial Authorization

Thymic Carcinoma - Initial Authorization

Thymic carcinoma initial: Diagnosis of thymic carcinoma

Thymic Carcinoma Reauthorization

Thymic Carcinoma - Reauthorization

Thymic carcinoma reauth: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Initial Therapy - Thymic carcinoma

Covered when ALL of the following are met:

Thymic carcinoma initial therapy: (1) Diagnosis of thymic carcinoma

Initial authorization criteria for thymic carcinoma

Reauthorization - Thymic carcinoma

Covered when the following is met:

Thymic carcinoma reauthorization: (1) Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Initial Therapy - Myeloid/Lymphoid neoplasms with eosinophilia

Covered when ALL of the following are met:

Myeloid/Lymphoid neoplasms initial therapy: (1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia

AND (2) Patient has a FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic or blast phase; Initial authorization requires both diagnosis and documented FLT3 rearrangement

Reauthorization - Myeloid/Lymphoid neoplasms

Covered when the following is met:

Myeloid/Lymphoid reauthorization: (1) Patient does not show evidence of progressive disease while on Sutent therapy

Authorization issued for 12 months

Coverage may be affected by state mandates, federal regulatory requirements, and the member's specific benefit plan; where such mandates apply they supersede this policy. UnitedHealthcare may also apply other utilization management programs (for example, supply limits) that affect approval or quantity dispensed. In some programs, approvals or reauthorizations may be issued automatically based on prior claim or medication history, diagnosis codes (ICD-10), and/or claim logic rather than manual review.

Use of Sutent outside the indications or without meeting the specific coverage criteria described in this policy may be considered not medically necessary. Documentation submitted must demonstrate the diagnosis and all criteria required for the requested indication; failure to meet the documented criteria may result in denial of coverage.

For reauthorization across covered indications, the policy requires documentation that the patient does not show evidence of progressive disease while on Sutent therapy. Evidence of disease progression while receiving Sutent is a reason to deny reauthorization. When reauthorization criteria are met, approvals are generally issued for 12 months.

Initial Therapy — Indication-Specific Requirements

Initial Therapy

Initial authorization criteria by indication

Initial therapy nodes: Refer to indication-specific initial authorization nodes (GIST requires diagnosis and prior progression/intolerance to listed agents or SDH-deficient GIST; RCC requires diagnosis plus relapsed/advanced or adjuvant high-risk post-nephrectomy; pNET requires progressive disease; listed sarcomas and other tumor types require corresponding diagnosis and criteria as specified)

Authorization generally issued for 12 months

Initial therapy criteria

Initial authorization criteria by indication

Thymic carcinoma initial: Diagnosis of thymic carcinoma

Myeloid/Lymphoid initial: Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia AND presence of FLT3 rearrangement in chronic or blast phase

Reauthorization / Continuation Requirements

Reauthorization/Continuation

Reauthorization requirement common to multiple indications

Continuation: Patient does not show evidence of progressive disease while on Sutent therapy

Typically granted for 12 months

Continuation therapy / Reauthorization

Reauthorization/continuation

Continuation requirement: Patient does not show evidence of progressive disease while on Sutent therapy

Authorization term: 12 months

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Sutent except for members under 19 years of age, whose prescriptions will automatically process without a coverage review. Authorization for approved indications is generally issued for 12 months. Some state mandates or member-specific benefit plan coverage may supersede these criteria.

Prior authorization required except members < 19 auto-process
Authorizations typically issued for 12 months
State mandates and member benefit plans may affect coverage

Documentation Required

Required Documentation for Initial Authorization

Initial authorization requires documentation of the diagnosis that matches the listed indications for the requested use of Sutent. Documentation should include relevant clinical notes, pathology, imaging, prior therapy history, and any molecular testing (e.g., FLT3 rearrangement when applicable).

Provide documentation that demonstrates the diagnosis and criteria for the requested indication
Include prior therapy history, imaging, pathology, and molecular testing when applicable

Documentation Required

Reauthorization Requirements

Reauthorization requires documentation that the patient is deriving clinical benefit and is not experiencing progressive disease while on Sutent therapy. Failure to show benefit or evidence of progression will result in denial of reauthorization.

Reauthorization contingent on no evidence of progressive disease
Clinical notes or imaging reports should document stability or improvement

Step Therapy

GIST Step Therapy Requirement

For gastrointestinal stromal tumor (GIST) indications, initial authorization requires documented history of disease progression on, contraindication to, or intolerance to imatinib (Gleevec), regorafenib (Stivarga), or standard-dose ripretinib (Qinlock) as applicable — unless the tumor is SDH-deficient. Ensure prior treatment history is clearly documented.

Document prior progression on or intolerance/contraindication to imatinib, regorafenib, or standard-dose ripretinib as applicable
SDH-deficient GIST is an alternate pathway for approval

Billing Rule

Programmatic Limits and Supply Rules

Supply limits and other utilization management programs may apply. UnitedHealthcare may use claim-history or programmatic rules to determine limits and approvals.

Supply limits may be in place
Other utilization management programs may apply

Note

Automated Approval and Claim-History Documentation

UnitedHealthcare may approve initial and reauthorization requests based solely on prior claims, medication history, diagnosis codes (ICD-10), and/or claim logic. Use of automated approval and re-approval processes varies by program and therapeutic class; providers should ensure claim histories and records accurately reflect prior therapies and diagnoses.

Automated approvals may use prior claims, medication history, and ICD-10 codes
Use of automated approval processes varies by program/therapeutic class

Denial Risk

General Denial Risk

Failure to meet the coverage criteria outlined in this policy or to provide adequate supporting documentation may result in denial of coverage. Providers should verify member-specific benefits and state mandates that may affect coverage determinations.

Insufficient documentation or unmet criteria may lead to denial
Verify member-specific benefits and applicable state mandates

Denial Risk

Reauthorization Denial Trigger

Reauthorization will be denied if there is evidence of progressive disease while on Sutent therapy. Providers must submit objective evidence demonstrating lack of progression and clinical benefit for continuation approvals.

Progressive disease while on therapy is a trigger for reauthorization denial
Submit objective evidence (imaging, clinical assessments) to demonstrate benefit

Step Therapy and Quantity Limits

Step	Requirement
GIST step 1	Must document prior history of disease progression on, a contraindication to, or intolerance to imatinib (Gleevec), regorafenib (Stivarga), or standard‑dose ripretinib (Qinlock) unless the patient has SDH‑deficient GIST; authorization issued for 12 months.

Background and Drug Information

Sutent (sunitinib malate) is an oral tyrosine kinase inhibitor with multiple oncologic approvals and recognized uses. It is indicated for gastrointestinal stromal tumor (GIST) after failure or intolerance to imatinib, for advanced or relapsed renal cell carcinoma (including select adjuvant high‑risk settings), and for progressive pancreatic neuroendocrine tumors; clinical guidance sources (for example, NCCN) also support use in select thyroid cancers, chordoma, meningioma, thymic carcinoma, and certain soft tissue sarcomas. UnitedHealthcare may consider additional program rules when authorizing Sutent, and automated approval processes using claim history or diagnosis codes may apply.

Definitions and Genomic Alterations

SDH-deficient GIST — definition and relevance as alternative indication

DefinitionA subtype of gastrointestinal stromal tumor (GIST) characterized by deficiency of the succinate dehydrogenase (SDH) complex (SDH-deficient GIST).

Policy relevanceListed as an alternative criterion allowing Sutent use for GIST without prior progression on or intolerance to imatinib, regorafenib, or standard-dose ripretinib (i.e., SDH-deficient GIST qualifies instead of prior therapy).

Clinical contextNCCN recognizes GIST subtypes including SDH-deficient tumors in guidance for Sutent use; SDH-deficiency denotes distinct tumor biology relevant to treatment selection.

Authorization noteWhen SDH-deficient GIST is present, the GIST step-therapy requirement for prior progression/intolerance/contraindication to imatinib, regorafenib, or ripretinib does not apply per the policy logic.

FLT3 rearrangement — genomic alteration qualifying certain neoplasms for therapy

DefinitionFMS-like tyrosine kinase 3 (FLT3) rearrangement — a genomic rearrangement involving the FLT3 gene detected in certain neoplasms (noted in chronic or blast phase).

Policy qualifying criterionPolicy requires documentation of a FLT3 rearrangement for coverage of Sutent in lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia (FLT3 rearrangement must be present in chronic or blast phase).

Indication sourceNCCN guidance cited in policy recognizes myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement as an indication for Sutent.

Authorization requirementInitial authorization for these neoplasms requires both the diagnosis of lymphoid, myeloid, or mixed lineage neoplasm with eosinophilia AND a documented FLT3 rearrangement in chronic or blast phase.

Policy Summary

PayerUnitedHealthcare

PolicySutent (sunitinib) prior authorization — Pharmacy Clinical Pharmacy Programs

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateMar 1, 2025

Key ActionSubmit prior authorization documenting diagnosis and required clinical history; members under 19 auto-process.

SourceLink

On This Page